23 Apr 2026 Recon: FDA approves Regeneron’s hearing loss gene therapy; Novo’s oral diabetes drug reduced blood sugar in children in Phase 3a study Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
21 Apr 2026 Recon: FDA approves Merck’s HIV pill combo; Moderna gets EU nod for combined flu, COVID shot in older patients Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
16 Apr 2026 Recon: Roche eyes new trial for Elevidys in bid for EU approval; Biovac wins funding to build biggest vaccine site in Africa Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
14 Apr 2026 Recon: FDA narrows search for new CBER director; Novo enters drug discovery pact with OpenAI Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
13 Apr 2026 Recon: FDA denies Replimune’s cancer drug over trial issues; Revolution’s cancer pill boosts survival in Phase 3 trial Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
09 Apr 2026 Recon: Amazon to sell Lilly’s weight-loss drug at kiosks in US; CDC delays report on COVID vaccine benefits Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
06 Apr 2026 Recon: White House wants to slash HHS budget by 12%; Neurocrine to purchase Soleno in $2.9B deal Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
02 Apr 2026 Recon: FDA approves Lilly’s GLP-1 pill Foundayo; White House announces 100% tariffs on some drugs Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
31 Mar 2026 Recon: Novo to offer discount Wegovy subscription for self-pay US consumers; Lilly to acquire Centessa in deal worth up to $7.8B Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
